Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus in CRPC with PI3K-AKT-mTOR deficiency
NCT03580239Phase 3Unknown
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Jan 2019
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of everolimus in prostate cancer (PCa), sponsored by The Second Hospital of Tianjin Medical University. Status: unknown.
02
Drugs
everolimus
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03580239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03580239.